This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Momentum in EDAP TMS S.A. (EDAP) Should Keep going
by Zacks Equity Research
EDAP TMS S.A. (EDAP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why "Trend" Investors Would Love Betting on EDAP TMS S.A. (EDAP)
by Zacks Equity Research
EDAP TMS S.A. (EDAP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Has Swedish Orphan Biovitrum (BIOVF) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Swedish Orphan Biovitrum (BIOVF) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
Strength Seen in EDAP TMS S.A. (EDAP): Can Its 13.4% Jump Turn into More Strength?
by Zacks Equity Research
EDAP TMS S.A. (EDAP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Has EDAP TMS (EDAP) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how EDAP TMS S.A. (EDAP) and Fstar Therapeutics, Inc. (FSTX) have performed compared to their sector so far this year.
EDAP TMS S.A. (EDAP) Stock Jumps 18.8%: Will It Continue to Soar?
by Zacks Equity Research
EDAP TMS S.A. (EDAP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ViewRay (VRAY) Catches Eye: Stock Jumps 7%
by Zacks Equity Research
ViewRay (VRAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
EDAP TMS' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in EDAP TMS.
EDAP's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor EDAP TMS.
EDAP TMS (EDAP) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
EDAP TMS (EDAP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
EDAP TMS S.A. (EDAP) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
EDAP TMS S.A. (EDAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will EDAP TMS Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor EDAP TMS.
Top Ranked Momentum Stocks to Buy for September 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 20th
EDAP TMS S.A. (EDAP) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in EDAP TMS S.A. (EDAP).
EDAP TMS S.A. (EDAP) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
EDAP TMS S.A. (EDAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
EDAP TMS (EDAP) Looks Good: Stock Adds 7.9% in Session
by Zacks Equity Research
EDAP TMS (EDAP) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Masimo (MASI) Introduces SafetyNet System in Dubai Hospitals
by Zacks Equity Research
Masimo's (MASI) proprietary Patient SafetyNet system's introduction in the Dubai market is in line with its strategy of becoming the dominant player in the pulse oximetry market.
athenahealth (ATHN) Shares Rally on Earnings Beat in Q2
by Zacks Equity Research
Solid expansion across athenahealth's (ATHN) ambulatory, hospital and population health platforms is expected to provide a competitive edge in the niche RCM space.
Intuitive Surgical (ISRG) Beats on Q2 Earnings & Revenues
by Zacks Equity Research
Intuitive Surgical posted solid numbers in the quarter under review, courtesy of rising customer adoption of procedures and growth in system placements.
AngioDynamics (ANGO) Shares Down Despite Q4 Earnings Beat
by Zacks Equity Research
AngioDynamics (ANGO) revenues declined year over year in the fourth quarter. Recall of the Acculis product line under the oncology segment is also a concern.
Stryker Poised on Solid Product Portfolio and Acquisitions
by Zacks Equity Research
On Jul 17, we issued an updated research report on Kalamazoo, MI-based Stryker Corporation (SYK), one of the largest medical device companies in the global orthopedic market.
Accuray's Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
Accuray (ARAY) announced its preliminary results for for the fourth quarter and fiscal 2017. Following the announcement, the company's stock lost over 2% in the last trading session to close at $4.70.
Accuray's Medical Systems to be Acquired by Dubai Hospital
by Zacks Equity Research
Accuray Inc. (ARAY) recently announced that it has signed an agreement with the Neuro Spinal Hospital in Dubai, United Arab Emirates.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
On Jul 12, we issued an updated research report on NY-based DENTSPLY SIRONA Inc. (XRAY) -- a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.
McKesson (MCK) Poised on Improving Generic and Brand Market
by Zacks Equity Research
On Jul 12, we issued an updated research report on San Francisco, CA-based McKesson Corporation (MCK).